Rachel Haurwitz, President and CEO, Caribou Biosciences
with Ross Andersen, Senior Editor, The Atlantic
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and in 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare. She is also a co-founder of Intellia Therapeutics where she is a member of the board of directors. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.